Patanjali, a renowned Indian wellness company, has made a significant breakthrough in the treatment of psoriasis, a chronic inflammatory skin disease. The company’s research on the condition has been published in the prestigious Journal of Inflammation Research, a publication of Taylor & Francis. The study, conducted on mice, demonstrates the effectiveness of Patanjali’s Psorogrit tablets and Divya-Taila in relieving the symptoms of psoriasis.
According to the research, Patanjali’s scientists administered Psorogrit tablets to two different preclinical models of mice with imiquimod and TPA-induced psoriasis, while also applying Divya-Taila to their skin. The results showed positive outcomes, indicating that the combination of these two products can potentially improve the clinical and pathological signs and symptoms of psoriasis.
Psoriasis is a debilitating condition characterized by the hyperproliferation of keratinocytes, infiltration of immune cells, and underlying vascular deformations, leading to shiny, silver-like scales and red patches on the skin, accompanied by intense itching. Patanjali’s Psorogrit and Divya-Taila aim to mitigate this condition in the long run. The company claims that these products are made from natural compounds such as giloy, amaltas, neem, haldi, seabuckthorn, and ashwagandha, which have been used to treat various skin conditions since ancient times.
Acharya Balkrishna, a key figure at Patanjali, stated that the company’s scientists have conducted extensive research and developed Psorogrit and Divya-Taila specifically for treating psoriasis. The publication of this research in a reputable international journal is a significant milestone for Patanjali, highlighting the company’s commitment to providing effective and natural solutions for various health conditions. The study’s findings offer new hope for individuals suffering from psoriasis, and further research is likely to be conducted to explore the full potential of Psorogrit and Divya-Taila in treating this condition.